UK: The Rise Of Corporate Venture Capital

Last Updated: 24 September 2013
Article by Tom Ward

As Corporate Venture Capital increasingly becomes an important part of the venture capital community, particularly across the technology and life sciences sectors, this article looks at recent trends, some of the deals done so far in 2013, and some of the issues commonly encountered when structuring a corporate venture capital transaction.

What is Corporate Venture Capital?

Corporate Venture Capital ("CVC") refers to the scenario where a large organisation (or its venture capital arm) makes a direct equity investment into a smaller (often privately held) company by taking a minority stake. The investment is usually driven by strategic goals, enabling the larger company to quickly access innovative technologies, creative output and to share R&D, whilst enabling a start-up company to access not just funding, but a wealth of marketing and buying power, distribution channels and product validation from a potential customer/partner (or indeed a potential acquirer).

A distinction should be made between Corporate Venture Capital and other forms of non-equity based corporate venturing. For example, a common form of corporate venturing used for R&D development may be structured by way of a collaboration agreement whereby the larger corporate provides funding in return for royalty rights or the right to share in the foreground intellectual property generated during the R&D collaboration.

This article looks at Corporate Venture Capital as an equity based investment, rather than non-equity based structures.

The Rise of the Corporate Venture Capital

Corporate Venture Capital is of course not a new concept and has been around for over 40 years. But from a somewhat chequered and volatile past, when Corporate Venture Capitalists ("CVCs") tended to invest at the end of an economic cycle, CVCs are becoming increasingly prominent and sophisticated, and are active in the early stages of the current economic cycle, particularly seen in the digital technology sector. Whilst CVCs continue to invest in later stage companies, they are also nurturing start-ups and plugging a gap in early stage and Series A deals which has been left by VC firms who, struggling to raise funds from their LPs, have adjusted their investment strategies in favour of less-risky later stage revenue-generative companies. It is perhaps symbolic of the existing venture capital ecosystem that the largest European VC fund to be raised in the first half of 2013 was Unilever's Venture II Fund, raising €350m and accounting for 39% of all funds raised for Q2 2013 1.

Tech and telecom

As we move towards an internet of things and smart digital technology, it is unsurprising that of the 126 CVC deals in the first half of 2013 surveyed by CB Insights, 4 out of every 10 deals funded the internet sector, hitting a five quarter high in Q2 2013. On a year on year basis, the number of deals in mobile technologies by CVCs was up 35% and the funding to that sector up 41% versus 20122. Google Ventures, Intel Capital, Samsung Ventures, Qualcomm Ventures, Comcast Ventures... there is a multitude of CVCs in this sector who are actively pursuing the next generation technologies.

Google Ventures is currently ranked the most active CVC investor. Its investments in OpenCoin in May 2013 (which was reportedly less than $200,000) and in Uber, a mobile technology and transportation business, in August 2013 (€258 million), shows that CVCs will invest both development capital in more mature businesses by way of Series C rounds and also provide more risky seed and Series A capital for unproven, pre-revenue start-ups.

An upward trend for Life Sciences Corporate Venture

In its analysis of private merger or acquisition transactions of US-based, venture capital-backed companies between 2005 and 2012, Silicon Valley Bank recently highlighted that CVC was part of the investor syndicate in 30% of all biotech Series A equity financings in 2012, twice that of the previous two years3. That upward trend has continued into 2013, with corporate venture capital funding to healthcare companies up 34% in Q1 2013 versus Q1 2012, with 39% more deals being funded in the same period.

In fact, over one third of the most active CVCs are healthcare focussed, with Novartis Ventures, GlaxoSmithKline, Merck and Johnson & Johnson amongst others actively investing in start-ups to stimulate promising, early-stage R&D innovation. GlaxoSmithKline's newly launched Action Potential Venture Capital fund in August 2013, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies, is a good example of a CVC investing in innovation as a way of sourcing new technologies and transformative medicines. The fund's first investment will be in SetPoint Medical, a developer of implantable devices for treating inflammatory diseases.

Structuring a Corporate Venture Capital deal

To a certain extent the structure of a Corporate Venture Capital deal looks and feels very similar to, and in most cases is the same as, a more traditional venture capital investment from a VC. On that basis, the standard documentation required to implement the transaction will usually be:

i. the initial term sheet;

ii. a subscription and shareholders agreement;

iii. a new set of articles of association to be adopted by the investee company on completion;

iv. disclosure letter (against the warranties contained in the subscription and shareholder agreement);

v. assignments of intellectual property from founders and other developers (if required); and

vi. service agreements for management and key employees.

The key principles will also be similar, in that the CVC taking a minority stake will want a board seat and veto rights over key commercial and corporate decision making. It will probably want to lock the management's shares in for a period, usually under good leaver/bad leaver provisions, and will want rights of first refusal over any further funding of the company, and potentially anti-dilution protection on any future down-round. The parties will also want to negotiate the class of shares to be issued to the CVC and the rights attached to such shares. Usually these would consist of a Preferred class of share giving the CVC a liquidation preference and a cumulative fixed dividend on its investment: a CVC will want to protect its downside as much as a traditional VC does if the company it is investing in does not turn out to be a success.

There will however in most cases be distinguishing features to the transaction which differentiate it from a more traditional VC fundraise, due to the CVC investing for strategic purposes. Each transaction will differ according to the specifics of the product, technology or market involved. For example, an internet or lifesciences CVC investing in a new innovative tech R&D company (with an eye on potentially acquiring that technology, or the company, in the future) may look to negotiate one or more of the following provisions:

Licensing deals

Where the investee company has manufactured products or platforms by way of a technical patented process, the R&D cost of which has been provided by the CVC, the CVC may want to both put in place a collaboration/knowledge sharing agreement during the R&D process and also a right of first refusal over the licensing of that technology. Some of the issues to be careful of when negotiating these arrangements can include:

  • ensuring there are robust confidentiality provisions in place dealing with the sharing of information, and a clear purpose for which that information can be used (and not in competition);

  • ensuring each party retains the rights in all of its background IP and that a party is not inadvertently given any rights in the other's background IP other than by way of non-exclusive licence for the purposes of the project;

  • negotiating licence terms regarding the foreground IP that arises during the R&D process. It is preferable to avoid joint ownership of foreground IP and care should be taken that foreground IP remains owned by the company, and that the CVC is only granted a licence to use such IP. This would usually be on an exclusive basis but founders will want to be careful that they do not unduly restrict the ability of the company to commercially exploit its IP with other parties in other markets and jurisdictions (or that appropriate exclusivity fees are agreed);

  • who will be responsible for filing, prosecution and enforcement of the patents and other IPRs?

Rights of first look over commercial output & distribution

Similarly, where the company has developed products or creative output which requires distribution (in particular to new markets and jurisdictions), the CVC will likely wish to negotiate first look rights over the distribution of that product/output across its channels. This may well of course have been the raison d'être for the investment having been offered and accepted in the first place, as a means for the company to achieve faster and higher growth by accessing the CVCs distribution channels, and the CVC to acquire new innovative products without having to devote resources to organic development. A few of the issues to bear in mind when negotiating the distribution arrangements will include:

  • the basis of the appointment and the extent of the territory. The CVC is likely to want for this to be exclusive in the main jurisdictions in which it operates but care should be taken that the company is not restricting its ability to commercially exploit its products and services through other channels (or that it is being adequately compensated by way of exclusivity fees if it is);

  • will there be any minimum purchase obligations in respect of any of the products or output?

  • what obligations will be imposed (if any) on the CVC in maintaining its distribution channels in the relevant territories, and will this be subject to minimum requirements;

  • care should be taken to comply with EU and UK competition laws, in particular avoiding any re-sale price maintenance or influencing the CVCs on-sale pricing.

Exit provisions & Call options

One of the main advantages of taking an investment from a larger corporation is that they are often not hamstrung by the vagaries of the term of life that LP structured funds are subject to (for example, most LPs operate over a 10 year lifespan and have to

wind down the fund and liquidate its investments, which can lead to a forced exit at an inappropriate time). Whilst of course this may also apply to the investment arm of a CVC which has structured itself as a more traditional LP, a larger corporate investing on its own balance sheet will not be required to exit or liquidate its investments at the end of a fixed period. A CVC can potentially therefore take a more flexible approach to the timing of an exit, and look to effect this when it is in its best interests to do so.

Whilst a more traditional VC would usually be looking for an economic exit, whether by way of a sale of its minority stake to a secondary investor, trade sale, IPO or a redemption of its Preferred shares, a strategic CVC investor may be more focussed on acquiring the company once the technology has been proven (following R&D) or once the company has reached a certain level of market penetration or profitability. Given the fast pace of current technological development, corporations are usually forced to make acquisitive decisions over a much shorter timescale, and therefore may at the outset have one eye firmly on acquiring the company over the short term and wish to adopt a flexible structure so that they can implement the acquisition at their option in an ever-changing market.

The most simplistic way in which the parties can deal with this without negotiating the detailed terms of the acquisition at the point of investment is to include a right of first refusal for the benefit of the investor over any proposed sale of the Company. This could also include the negotiation of a right for the investor to match any third party offer and to make any Drag rights in the articles of association conditional on the investor being given a window and opportunity to purchase the company itself. However, in some cases it may be in the CVCs interests to have more certainty over the terms of the acquisition, particularly if the CVC is sensitive to competition and wishes to control the timing of the acquisition. In such circumstances the CVC may wish to negotiate a "call" option over the shares held by the founders and other shareholders to enable it to become the 100% owner at a future date. In a similar fashion, the founder(s) may want the corresponding right to "put" their shares to the CVC in order to require it to buy them out on similar terms). This can be an attractive position for founder(s) as it gives them a natural exit opportunity by selling out to the CVC under the option arrangements. Whilst this gives both parties a degree of certainty over the sale and acquisition of the business, it does of course mean that when negotiating the investment the founder(s) must bear in mind that they are also potentially negotiating the eventual sale of the company, and locking-themselves in to a sale to one suitor, when there may be more interested parties, and a more competitive process, later on in the company's lifecycle.

A Call Option granted in favour of the CVC will give it the right to acquire the remaining shares in the company at future date and at an agreed valuation. Some of the potential issues to consider when negotiating the put & call options will be:

  • how and when will the Call option be capable of being exercised? Will this be at the investor's election at any time following the investment or should there be a period of time during which the options cannot be exercised? Alternatively the option could become exercisable on the occurrence of a predefined event, such as successful completion of R&D, clinical trials, product launch or otherwise once the company has reached a certain level of sales, profitability or market penetration;

  • care should be taken to ensure that any conditions to exercise are capable of being easily measured and independently verified, and that they are realistically achievable;

  • how is the company to be valued at the time the option is exercised? If the company is generating revenues and profit, will the valuation be calculated by reference to EBITDA or sales, and in either case, over what timeframe? For R&D companies a valuation defined by EBITDA or sales figures are unlikely to appropriate and more complex considerations should be had in terms of valuing the IP which is being acquired;

  • should there be any minimum or maximum floor to the valuation given to the company under the option? Whilst a maximum floor may give a CVC certainty that it will pay no more than a certain amount to acquire the company, it is likely to act as a disincentive to founder(s) and preferably should be avoided;

  • the grant and exercise (and disposal) of options can also give rise to complex tax issues. For example, if care is not taken with the structuring of put and call options, the founder(s) may be deemed to have disposed of their shares at the date of grant of the options and become liable to tax. Careful consideration should therefore be given to the tax structuring and specialist tax advice should be taken.

Corporate Venture Capital in 2014

Given that the figures released for 2012 and for the first half of 2013 show a continued increase in the amount of Corporate Venture Capital in early stage and development capital deals, it is likely that CVC will continue to play an important role in the US and European venture landscape, alongside traditional VCs and business angels.

In the UK, there have been recent calls4 for the UK Government to bring back a scheme similar to the previous Corporate Venturing Scheme ("CVS") which was abandoned in March 2010. The CVS was introduced in 2000 to incentivise and encourage CVC activity in the UK and provided tax reliefs for corporate equity investment in the same types of companies as those qualifying under the current Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) scheme.

Primarily, if the qualifying criteria for CVS were met, the company making the investment would benefit from:

(A) Investment Relief: relief against corporation tax of up to 20% of the amount subscribed for full risk ordinary shares;

(B) Deferral Relief: deferral of tax on chargeable gains arising on the disposal for shares on which investment relief has been obtained, if the gains are reinvested in new shares for which investment relief is obtained; and

(C) Loss relief: relief against income for capital losses arising on disposals of shares on which investment relief has been obtained, net of the investment relief.

Having expired at the end of March 2010, the scheme was not renewed in the following Budget due to poor take up; however, with the deployment of corporate venturing again on the agenda of companies looking to access the innovation of the UK's technology and life sciences community, and with VCs focussing on later stage investments, an effective economic and fiscal policy on Corporate Venturing would likely prove to be a boost for the venture capital ecosystem.

  4. See:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.